Impact of a pharmacist-directed intervention in postmenopausal women after fracture

American Journal of Health-System Pharmacy

Volumn 69, Issue 6, 2012, Pages 504-509

  Heilmann, Rachel M F ^a   Friesleben, Cari R ^a   Billups, Sarah J ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Bone density; Bone resorption inhibitors; Clinical pharmacists; Clinical pharmacy; Compliance; Diagnosis; Fractures; Osteoporosis; Patients; Pharmaceutical services; Postmenopause

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN DERIVATIVE; PARATHYROID HORMONE[1-34]; RALOXIFENE; VITAMIN D;

AGED; ARTICLE; BONE DENSITY; CLINICAL PHARMACY; FEMALE; FRACTURE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PHARMACEUTICAL CARE; PHARMACIST; POSTMENOPAUSE; PRIORITY JOURNAL; REGISTERED NURSE; SCREENING TEST;

EID: 84858994169     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110309     Document Type: Article

References (27)

1. National Osteoporosis Foundation. Bone health basics. www.nof.org/about osteoporosis/bonebasics/whybonehealth (accessed 2011 May 13).
2. Berry SD, Samelson EJ, Hannan MT et al. Second hip fracture in older men and women: the Framingham study. Arch Intern Med. 2007; 167:1971-6. (Pubitemid 47606637)
3. Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab. 2000; 85:4118-24. (Pubitemid 32055362)
4. National Osteoporosis Foundation. Clinicians guide to prevention and treatment of osteoporosis. www.nof.org/ sites/default/files/pdfs/NOF-Clinician Guide2009-v7 (accessed 2011 Jul 22).
5. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003; 9:544-63.
6. World Health Organization. Prevention and management of osteoporosis. http:// whqlibdoc.who.int/trs/who-trs-921.pdf (accessed 2011 May 13).
7. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause. 2006; 13:340-67.
8. Andrade SE, Majumdar SR, Chan KA et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003; 163:2052-7. (Pubitemid 37151247)
9. Feldstein A, Elmer PJ, Orwoll E et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based guideline implementation. Arch Intern Med. 2003; 163:2165-72. (Pubitemid 37248781)
10. Ryder KM, Shorr RI, Tylavsky FA et al. Correlates of use of antifracture therapy in older women with low bone mineral density. J Gen Intern Med. 2006; 21:636-41. (Pubitemid 43801495)
11. Gold DT, Alexander IM, Ettinger MP. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother. 2006; 40:1143-50. (Pubitemid 43886973)
12. Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81:1013-22. (Pubitemid 44175011)
13. National Committee for Quality Assurance. Osteoporosis management in women who had a fracture: percentage of women 67 years and older who suffered a fracture, and who had either a bone mineral density (BMD) test or prescription for a drug to treat or prevent osteoporosis in the six months after the fracture. www.qualitymeasures.ahrq.gov/ content.aspx?id=14958 (accessed 2011 May 13).
14. Nadrash T, Plushner S, Delate T. Clinical pharmacists' role in improving osteoporosis treatment rates among eldery patients with untreated atraumatic fractures. Ann Pharmacother. 2008; 42:334-40. (Pubitemid 351429597)
15. Che M, Ettinger B, Liang J et al. Outcomes of a disease-management program for patients with recent osteoporotic fracture. Osteoporos Int. 2006; 17:847-54. (Pubitemid 43781498)
16. Dell R, Green D, Schelkun SR et al. Osteoporosis disease management: the role of the orthopaedic surgeon. J Bone Joint Surg Am. 2008; 90:188-94.
17. Rolnick SJ, Kopher R, Jackson J et al. What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting? Menopause. 2001;8:141-8. (Pubitemid 32199680)
18. Rozental TD, Makhni EC, Day CS et al. Improving evaluation and treatment of osteoporosis following distal radial fractures. A prospective randomized intervention. J Bone Joint Surg Am. 2008;90:953-61. (Pubitemid 351632637)
19. Harrington JT, Lease J. Osteoporosis disease management for fragility fracture patients: new understandings based on three years' experience with an osteoporosis care service. Arthritis Rheum. 2007;57:1502-6. (Pubitemid 350308850)
20. Gardner MJ, Brophy RH, Demetrakopoulos D et al. Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. J Bone Joint Surg Am. 2005; 87:3-7. (Pubitemid 40094132)
21. National Committee for Quality Assurance. The state of health care quality 2008. www.ncqa.org/Portals/0/ News room/SOHC/SOHC-08.pdf (accessed 2011 May 13).
22. Lo JC, Pressman AR, Omar MA et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006; 17:922-8. (Pubitemid 43781507)
23. Tosteson AN, Grove MR, Hammond CS et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003; 115:209-16. (Pubitemid 37338146)
24. Papaioannou A, Kennedy CC, Dolovich L et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging. 2007; 24:37-55. (Pubitemid 46148080)
25. Downey TW, Foltz SH, Boccuzzi SJ et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J. 2006; 99:570-5. (Pubitemid 43999919)
26. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005; 80:856-61. (Pubitemid 40911458)
27. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006; 38:S2-6.